What stands out about Ethan Drower and his role at CiteMed

[Wei Zhang]

From my experience, adoption in this space often comes from referrals rather than marketing. If CiteMed is being used quietly by regulatory consultants or device manufacturers, that might not show up in public narratives yet. Lack of visible traction does not necessarily mean lack of activity. It just means outsiders have limited visibility. Founder interviews are sometimes the only public window, which can distort perception.

That is a good point about visibility. Without public case studies or metrics, it is hard to tell whether quiet adoption is happening or not. I guess that is just the reality with private companies in specialized niches. It makes discussions like this more about interpretation than facts. Still useful, but with clear limits.

 

[Steven Campbell]

I also think timing matters a lot. EU medical device regulation has gone through changes in recent years, and many companies are still adjusting. A platform might be early to the market and waiting for demand to catch up. Founder interviews during that phase can sound aspirational because the future is still uncertain. That does not invalidate the idea, it just frames it differently.